Strategic Sector Expansion
Braun Stacey Associates Broadens Portfolio with Increased Stakes in Key Biotech and Healthcare Firms
Anonymous
Key Points
1
Insider Flemming Steen Jensen sold 19,460 Ascendis Pharma A/S shares on May 11 at an average price of $238.49, signaling insider activity not captured in Braun Stacey’s summary.
2
Royal Bank of Canada increased its QXO stake by 67.5% to 119,688 shares in the first quarter.
3
AQR Capital Management LLC took a new position in QXO during the first quarter.
4
Riverstone Advisors LLC boosted its IQVIA stake by 12.2% in the first quarter.
5
Louisiana State Employees Retirement System opened a new position in IQVIA during the first quarter, worth about $1,467,000.
Braun Stacey Associates Inc. added to its positions in biotech, healthcare, and retail during the first quarter of 2026, with its biggest new bet being a $11.9 million stake in IQVIA Holdings Inc. The firm also lifted its holdings in Ascendis Pharma A/S by 10% to 130,992 shares worth roughly $30 million, signaling a deliberate push into high-growth sectors, according to Watchlist News.
The moves are part of a broader reshaping of Braun Stacey's $3.0 billion portfolio. The firm cut some positions — trimming Western Digital by 14.7% and AppLovin by 13.1% — while concentrating fresh capital in companies with strong buyback programs and consolidation stories, according to Ticker Report.
Braun Stacey Bets Big on IQVIA's AI-Driven Rebound
Braun Stacey opened a new position in IQVIA Holdings, buying 69,628 shares worth about $11.9 million. The timing was sharp. On May 7, IQVIA's board authorized a $2.0 billion increase to its share repurchase program, bringing total buyback capacity to $3.2 billion. The stock jumped 9.3% in late May as investors warmed to the company's AI strategy.
IQVIA CFO Michael Fedock told the Bank of America Global Healthcare Conference that AI fears are becoming a "tailwind" as clients adopt IQVIA's data tools. InvestingPro flagged the stock as undervalued in May, trading at $178.64 against a fair value estimate of $225.58. Riverstone Advisors LLC also boosted its IQVIA stake by 12.2% in the first quarter, and Louisiana State Employees Retirement System opened a new position worth about $1,467,000.
QXO's $30 Billion Deal Spree Draws Institutional Crowd
Braun Stacey raised its QXO stake by 2.9% to 1,336,330 shares, valued near $26 million. QXO is led by Brad Jacobs, who is applying his same playbook from United Rentals and XPO to the fragmented building products industry. In just 13 months, QXO announced or closed more than $30 billion in deals, including a $2.25 billion acquisition of Kodiak Building Partners in April and a landmark $17 billion deal for TopBuild Corp.
Jacobs said that once the TopBuild deal closes, "QXO will be the second largest publicly traded building products distributor in North America," with a goal of reaching $50 billion in annual revenue within a decade. Royal Bank of Canada increased its QXO stake by 67.5% to 119,688 shares in Q1, and AQR Capital Management took a new position. RBC Capital lowered its price target to $28 from $30 in April, citing housing market weakness, but kept an "Outperform" rating.
Ascendis Pharma Insider Sells as Braun Stacey Buys More
Braun Stacey added to its Ascendis Pharma position, bringing its stake to 130,992 shares worth $30 million. The biotech completed a technical shift in April 2026, moving from American Depositary Shares to a direct listing of ordinary shares on the Nasdaq to make trading simpler for global investors. The company continues to roll out products including SKYTROFA and YORVIPATH.
Not everyone is holding. Insider Flemming Steen Jensen, an EVP at Ascendis, sold his entire direct holding of 19,460 shares on May 11 at an average price of $238.49 per share, netting roughly $4.64 million. Analysts note such sales often reflect personal financial planning. Separately, CFO Scott Thomas Smith bought 100 ordinary shares at $219.00 on June 2 — a small but notable signal of insider confidence.
Urban Outfitters Beats Forecasts but Faces Tariff Timing Risk
Braun Stacey lifted its Urban Outfitters position by 3.2% to 265,442 shares worth about $16.8 million. The retailer gave investors something to cheer. Urban Outfitters reported Q1 earnings of $1.30 per share, beating the $1.17 forecast. Revenue hit a record $1.48 billion, up 11.4% year over year. The flagship brand posted a +2% comparable sales gain, reversing a multi-year slide.
The good news comes with a catch. Urban Outfitters shifted shipments from air to ocean freight to avoid tariff costs, which cuts shipping bills but adds weeks to delivery times. Analysts warn this introduces serious "fashion risk" heading into the critical fall and holiday season, since slower transit means fewer chances to react if a style misses with shoppers. The Nuuly rental subscription service, which grew 60%, remains the brand's brightest long-term signal.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
14
Articles
9
Reach
23
A
AnonymousAuthor
